Senseonics initiated with a Buy at Lake Street

Lake Street analyst Ben Haynor initiated coverage of Senseonics (SENS) with a Buy rating and $1 price target Senseonics pioneered implantable continuous glucose monitors and has now introduced the first and only implantable CGM, Eversense 365, the analyst tells investors. Senseonics has laid out a long-term user forecast which contemplates reaching 12,000 patients this year, 24,000 next year, and over 50,000 by 2027, notes the analyst, who argues that reaching the company’s patient forecasts “does not seem to be a heavy lift.”